Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
VEGFR protein kinase inhibitor Cediranib, 5 mg  

VEGFR protein kinase inhibitor Cediranib, 5 mg

4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-1-yl-propoxy)-quinazoline

Cediranib is a highly potent and orally available tyrosine kinase inhibitor (TKI), targeting VEGF receptor.
Synonyms: AZD 2171

More details

PKI-CEDIR-005

Availability: within 3 days

110,50 €

Background: Cediranib is a highly potent and orally available tyrosine kinase inhibitor (TKI), targeting VEGF receptor; thereby blocking VEGF-signaling, angiogenesis, and tumor cell growth.

Chemical formula: C25H27FN4O3
Molecular weight: 450.51 g/mol
Purity: 99%
Appearance: Off-white Solid
Solubility: Soluble in DMSO
CAS Number: 288383-20-0

Manufacturer:  Axon Medchem BV

PLEASE NOTE: This product is designed for research purposes and can only be delivered to academic and business customers.  

References

SR Wedge et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 2005, 65 (10), 4389–400.
 
G Goss et al. A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine. Eur. J. Cancer 2008, 45, 782.
 
P Nikolinakos & JV Heymach. The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies. J. Thorac. Oncol. 2008, 3 (6 Suppl 2): S131–4.
 
CA Heckman et al. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res. 2008, 68(12), 4754-4762.

The following products could also be interesting for you: